These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
476 related articles for article (PubMed ID: 29526541)
1. Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism. Coleman CI; Turpie AGG; Bunz TJ; Beyer-Westendorf J Am J Med; 2018 Aug; 131(8):933-938.e1. PubMed ID: 29526541 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism. Coleman CI; Bunz TJ; Turpie AGG Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state. Coleman CI; Turpie AGG; Bunz TJ; Baker WL; Beyer-Westendorf J Thromb Res; 2018 Mar; 163():132-137. PubMed ID: 29407625 [TBL] [Abstract][Full Text] [Related]
4. Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism. Kohn CG; Bunz TJ; Beyer-Westendorf J; Coleman CI Eur J Haematol; 2019 Feb; 102(2):143-149. PubMed ID: 30328143 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism. Coleman CI; Turpie AGG; Bunz TJ; Beyer-Westendorf J J Thromb Thrombolysis; 2018 Oct; 46(3):339-345. PubMed ID: 29881958 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation. Martinez BK; Sood NA; Bunz TJ; Coleman CI J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data. Costa OS; Beyer-Westendorf J; Ashton V; Milentijevic D; Moore KT; Bunz TJ; Coleman CI J Thromb Thrombolysis; 2021 Feb; 51(2):349-358. PubMed ID: 32588288 [TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs. Spyropoulos AC; Ashton V; Chen YW; Wu B; Peterson ED Thromb Res; 2019 Oct; 182():159-166. PubMed ID: 31493618 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study. Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of rivaroxaban versus warfarin in patients with unprovoked venous thromboembolism: A propensity-score weighted administrative claims cohort study. Coleman CI; Peacock WF; Bunz TJ; Beyer-Westendorf J Thromb Res; 2018 Aug; 168():31-36. PubMed ID: 29883907 [TBL] [Abstract][Full Text] [Related]
12. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism. Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881 [TBL] [Abstract][Full Text] [Related]
13. Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE. Coleman CI; Turpie AGG; Bunz TJ; Beyer-Westendorf J; Baker WL Am J Med; 2019 Apr; 132(4):498-504. PubMed ID: 30582894 [TBL] [Abstract][Full Text] [Related]
14. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study. Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376 [TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis. Coleman CI; Kreutz R; Sood NA; Bunz TJ; Eriksson D; Meinecke AK; Baker WL Am J Med; 2019 Sep; 132(9):1078-1083. PubMed ID: 31054829 [TBL] [Abstract][Full Text] [Related]
16. Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism. Coleman CI; Beyer-Westendorf J; Bunz TJ; Mahan CE; Spyropoulos AC Clin Appl Thromb Hemost; 2018 May; 24(4):575-582. PubMed ID: 29514466 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study. Signorelli JR; Gandhi AS J Oncol Pharm Pract; 2019 Mar; 25(2):362-368. PubMed ID: 29157146 [TBL] [Abstract][Full Text] [Related]
18. Rivaroxaban Versus Warfarin and Risk of Post-Thrombotic Syndrome Among Patients with Venous Thromboembolism. Søgaard M; Nielsen PB; Skjøth F; Kjældgaard JN; Coleman CI; Larsen TB Am J Med; 2018 Jul; 131(7):787-794.e4. PubMed ID: 29476744 [TBL] [Abstract][Full Text] [Related]
19. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism. Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990 [TBL] [Abstract][Full Text] [Related]
20. Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin. Coleman CI; Costa OS; Brescia CW; Vardar B; Abdelgawwad K; Sood N Cardiovasc Diabetol; 2021 Feb; 20(1):52. PubMed ID: 33637082 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]